The 'cell of origin' of the second most ... the risk of lung cancer. In the future, it could be possible to look for these sections in those at risk of cancer and develop treatment plans to ...

Almost 50,000 lung cancer patients have not been seen on time over the last 10 years, with thousands currently waiting more ...

The "cell of origin" of the second most common lung cancer and the way that it becomes dominant in the lung have been ...

Low-dose computed tomography is more sensitive than chest radiography in detecting lung metastases or second primary lung cancer in patients with HNSCC.

A new study presented at ESTRO 2025 introduces the RAPID-RT study, which uses an innovative rapid-learning approach to ...

To check if the findings apply to humans, the team also analyzed lung and windpipe tissue from smokers and non-smokers. They ...

Opdivo (nivolumab) is a brand-name IV infusion prescribed for non-small cell lung cancer (NSCLC ... refers to the length of time people lived while receiving treatment. Another trial found ...

"Lung cancer is notoriously awful because when it is found, a lot of the time it is Stage 3 and 4, which is hard to treat, ...

Researchers have shown that activation of the protein YAP, known to help cancer cells survive treatment, behaves very ...

How one man, along with his care team, turned an all-consuming cancer diagnosis into a management strategy with inspiration ...